Mirum Pharmaceuticals, Inc. (MIRM) Misses Q4 EPS by 155c

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) reported Q4 EPS of ($1.85), $1.55 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $99.41 million versus the consensus estimate of $95.4 million.

For earnings history and earnings-related data on Mirum Pharmaceuticals, Inc. (MIRM) click here.

You May Also Be Interested In

• EquipmentShare.com (EQPT) Mentioned as Short at Blue Orca
• Acadia Pharmaceuticals (ACAD) PT Lowered to $34 at BMO Capital Amid Heavy Selling
• BlackBerry shares gain premarket as Q2 results, guidance beat estimates